MARKET

HCM

HCM

Hutchmed (China) Limited
NASDAQ
17.36
+0.41
+2.42%
Pre Market: 17.98 +0.62 +3.57% 08:00 12/03 EST
OPEN
17.43
PREV CLOSE
16.95
HIGH
17.64
LOW
17.19
VOLUME
1
TURNOVER
0
52 WEEK HIGH
21.92
52 WEEK LOW
11.93
MARKET CAP
3.03B
P/E (TTM)
-69.5234
1D
5D
1M
3M
1Y
5Y
1D
HUTCHMED, Innovent's ELUNATE-TYVYT Combo Secures Approval In China For Endometrial Cancer
NASDAQ · 5h ago
Hutchmed announces Elunate, Tyvyt NDA granted approval in China
TipRanks · 6h ago
Hutchmed And Innovent Biologics Announce That Elunate (Fruquintinib) And Tyvyt (Sintilimab) Combination Has Received Conditional Approval In China For Advanced Endometrial Cancer With Mismatch Repair Proficient Tumors That Have Failed Prior Systemic Therapy And Are Not Candidates For Curative Surgery Or Radiation
Benzinga · 7h ago
HUTCHMED AND INNOVENT JOINTLY ANNOUNCE NMPA CONDITIONAL APPROVAL FOR ELUNATE® (FRUQUINTINIB) IN COMBINATION WITH TYVYT® (SINTILIMAB INJECTION) FOR THE TREATMENT OF ADVANCED ENDOMETRIAL CANCER
Reuters · 7h ago
Weekly Report: what happened at HCM last week (1125-1129)?
Weekly Report · 1d ago
Reported Thursday, HUTCHMED Confirms ORPATHYS (Savolitinib) Retains Spot On China's National Reimbursement Drug List
Benzinga · 4d ago
HUTCHMED Announces Renewal of Inclusion for ORPATHYS® in China's National Reimbursement Drug List Effective January 1, 2025
Barchart · 5d ago
HUTCHMED Announces Renewal Of ORPATHYS Inclusion In China's NRDL
NASDAQ · 5d ago
More
About HCM
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

Webull offers HUTCHMED (China) Ltd (ADR) stock information, including NASDAQ: HCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HCM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HCM stock methods without spending real money on the virtual paper trading platform.